8:38 AM
 | 
Mar 30, 2018
 |  BC Week In Review  |  Clinical News  |  Regulatory

Japan approvals include Hemlibra, Shingrix Galafold

Japan approved a basket of drugs including hemophilia drug Hemlibra emicizumab from Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), shingles vaccine Shingrix from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Fabry's disease drug Galafold migalastat from Amicus Therapeutics Inc. (NASDAQ:FOLD).

Japan's Ministry of Health, Labour and Welfare (MHLW) approved Hemlibra to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A with Factor VIII inhibitors. Chugai, which is majority owned by Roche (SIX:ROG; OTCQX:RHHBY), initially developed Hemlibra and Roche opted into development of the product in 2014. The bispecific mAb that binds Factor IXa and Factor X is also approved in the U.S. and EU.

GSK said that both Japan's MHLW and the European Commission approved Shingrix for adults ages 50 and older....

Read the full 587 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >